A Phase 3, Open-label, Multicenter, Randomized Study of Sequential Zevalin (Ibritumomab Tiuxetan) Versus Observation in Patients at Least 60 Years of Age With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy

Status
Active
Cancer Type
Non-Hodgkin Lymphoma
Trial Phase
Phase III
Eligibility
60 and over, Male and Female
Study Type
Treatment
NCD ID
NCT01510184
Protocol IDs
SPI-ZEV-11-301 (primary)
Study Sponsor
Spectrum Pharmaceuticals, Incorporated

Summary

The purpose of this study is to evaluate the efficacy and safety of Zevalin compared with observation alone in patients who are in PET-negative complete remission after first-line R-CHOP or R-CHOP like therapy.